Hydrogen Therapy Helps Rare Autoimmune Disease Patient After Drug Failures
Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report
Research hubs: Rheumatoid Arthritis · Immune System · Musculoskeletal System
- Evidence type
- Case report or series · Human study
- Authors
- Han-Luen Tsai, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2026
- PMID
- 41482402
- Study Type
- Human
- Participants
- 1
- Delivery
- Gas (Sustained Release)
- Dose
- oral molecular hydrogen capsule therapy initiated in October 2023
- Duration
- 16 months
- Funding
- National Science and Technology Council, Taiwan (NSTC 112-2314-B-016-033); National Science and Technology Council, Taiwan (NSTC 113-2314-B-016-052); National Science and Technology Council, Taiwan (NSTC 114-2314-B-016-052-MY3); Tri-Service General Hospital, Taiwan (TSGH-E-112218); Tri-Service General Hospital, Taiwan (TSGH-E-113238)
- Conflicts of interest
- None declared
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 1 (OpenAlex, as of November 2026)
- Country
- Taiwan
TL;DR
Hydrogen capsule therapy improved immune balance and reduced disease activity in a patient with severe autoimmune overlap syndrome resistant to standard treatments.
Key Finding
A patient with treatment-resistant Rhupus syndrome showed significant clinical improvement and reduced inflammation markers after adding oral molecular hydrogen therapy to his existing medications, with sustained disease control and ability to discontinue prednisone.
Summary
This case report describes a single patient with Rhupus syndrome—a rare overlap condition combining rheumatoid arthritis and lupus—who had severe reactions to multiple standard medications. When molecular hydrogen (H2) capsules were added to his existing treatment in October 2023, his disease improved significantly, with blood markers normalizing and his steroid dose reduced to zero. The improvement was sustained over the following months.
Practical Takeaway
This is a single case report, not a controlled study, so it cannot prove that hydrogen therapy caused the improvement or that it will work for others with similar conditions. While the patient's response is noteworthy, early evidence from one case is not sufficient to recommend hydrogen therapy as a standard treatment. Much larger and more rigorous studies would be needed before drawing conclusions about its effectiveness for autoimmune diseases.
Abstract (excerpt)
Background/aim: Rhupus syndrome, an overlap of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), is a rare condition characterized by heterogeneous clinical manifestations and difficult management. Conventional therapies, including glucocorticoids, disease-modifying anti-rheumatic…